Table 8. Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) based on HCV genotype.
| Hepatitis C virus (HCV) genotype | ICERs per QALY1 |
| 1 | Treatment-naïve: less than $0 to $31,4522 |
| Interferon-experienced patients: $84,744 to $178,295 | |
| 2 | US$ 35,500 to US$238,0002,3 |
| 3 | US$ 410,5182 |
| 4 | US$ 34,349 to US$ 80,7932 |
1
When the ICER is determined, it is compared to the willingness to pay threshold, which is typically considered $50,000 to $100,000/QALY;
2
Depending on presence or absence of cirrhosis;
3
In treatment-naïve patients without cirrhosis, the manufactures price for sofosbuvir led to ICERs above the willingness to pay threshold. Negotiating lower cost can lead to ICERs dropping to acceptable levels.